Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is featured in a BioMedWire editorial titled "The Quest to Repair What Multiple Sclerosis Takes Away", which examines the urgent need for novel treatments for multiple sclerosis (MS). MS is a progressive neurological disease affecting over 2.9 million people worldwide. Current therapies can slow disease progression but cannot stop it or reverse damage, leaving patients with few options as the disease advances.
Quantum BioPharma is developing Lucid-MS, a patented, first-in-class drug candidate designed to directly target the myelin sheath damaged by MS. Unlike existing treatments that primarily modulate the immune system, Lucid-MS aims to prevent and reverse myelin degradation. The company announced that Lucid-MS is preparing to advance into Phase 2 clinical trials, marking a significant step toward a potential disease-modifying therapy that could address the underlying pathology of MS.
The editorial highlights the limitations of current MS treatments, which often focus on reducing inflammation and immune attacks on myelin but do not promote repair. Lucid-MS represents a paradigm shift by targeting remyelination, the process of restoring damaged myelin sheaths. In preclinical models, Lucid-MS has shown the ability to prevent and reverse myelin degradation, offering hope for restoring neurological function in MS patients.
Quantum BioPharma is a biopharmaceutical company building a portfolio of innovative assets for neurodegenerative, metabolic, and alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum is focused on Lucid-MS. The company also developed UNBUZZD, a product for alcohol misuse, and retains a 19.84% stake in Unbuzzd Wellness Inc. as of March 31, 2026, along with royalty payments.
The advancement of Lucid-MS into Phase 2 trials is a critical milestone not only for Quantum BioPharma but also for the MS community. If successful, Lucid-MS could become the first therapy to directly repair myelin damage, potentially changing the treatment landscape for MS. The editorial underscores the importance of pursuing novel approaches like Lucid-MS to address the significant unmet need in MS care.
For more information on Quantum BioPharma, visit the company's newsroom at https://ibn.fm/QNTM.
